Special Issue

Psoriasis and Metabolic Syndrome

Message from the Guest Editor

Psoriasis is a chronic autoimmune and inflammatory disease affecting 2–4% of the population. To date, psoriasis has been regarded as a systemic disease closely related to numerous cardiometabolic disorders, especially metabolic syndrome (MS), which affects 20–60% of psoriatic. People with psoriasis have a shortened life expectancy, mainly due to cardiovascular diseases and increased relative risk of mortality in comparison to the general population, which correlates with the severity of the disease. The multidirectional relationship of psoriasis with various comorbidities is translated by common genetic or immunological inflammation, but especially with systemic metabolically driven inflammation, which is crucial in psoriasis pathogenesis and leads to the development of atherosclerosis, insulin resistance, and further cardiometabolic complications. There have been continuous research efforts searching for novel markers and metabolites to evaluate or screen for cardiometabolic risk in order to enable early detection, followed by more effective and newer therapeutic interventions.

Guest Editor

Prof. Anna Baran

Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland

Deadline for manuscript submissions

31 January 2026



Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/si/216682

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites



Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/journal/metabolites

MDPI

About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).